Illumina to acquire SomaLogic, accelerating its proteomics business and advancing the company's multiomics strategy

Illumina, Inc. announced a definitive agreement to acquire SomaLogic, a leader in data-driven proteomics technology, and other specified assets from Standard BioTools for $350 million in cash plus up to $75 million in performance-based milestones and royalties. The acquisition aims to enhance Illumina's presence in the expanding proteomics market and advance its multiomics strategy.